Recent phase I/II trials have reported manageable toxicity profiles and promising anti-tumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab, and JS001) with/without chemotherapy in the treatment of recurrent/metastatic nasopharyngeal carcinoma[110-112]. This evidence concerns the gene PDCD1 and neoplasm.